Insider trade

Officer sold ~$29K of INCY shares in the open market

Traded Nov 17, 2025 · Filed Nov 19, 2025

IncyteINCY

~$29K
Reported value · 278 sh @ $104.36: 27K
Holds after · shares reported: +9.6%
stock since the trade · S&P 500 +16.4%, $104.17 → $114.13 on Oct 5

Why it stands out

Incyte's & General Counsel sold $29K of Incyte shares. It happened by itself, for taxes or pay.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Nov 17, 2025
Reporting period: Not applicable
Filed with the SEC: Nov 19, 2025

Officer$25K–$100KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$29,012

Shares × reported transaction price

Timing vs results

20 days after results of Oct 28, 2025, 85 days before results of Feb 10, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $104.17 on Nov 17, 2025, within 4% of its 52-week high, after a 19% rise over the previous 30 trading days

52-week range $55.17 (Apr 10, 2025) to $108.26 (Nov 12, 2025), 92% of the way up, from 250 adjusted closes. 30 trading days earlier: $87.23 on Oct 6, 2025. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Zynyz on Dec 17, 2025, 30 days after this trade.

New use approved (efficacy supplement). Active ingredient: Retifanlimab-Dlwr. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+2.6%	+4.7%	−2.1%
30 days	−1.0%	+5.0%	−6.0%
90 days	+1.2%	+5.2%	−4.0%
180 days	−6.0%	+12.4%	−18.5%

Past results only. Not a forecast.

Source receipt

Record ID: 0001995298-25-000014
Filed / recorded: Nov 19, 2025, 9:08 PM UTC
Added to OQRO: Oct 2, 2026, 12:28 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: INCYTE CORP
Issuer CIK: 879169
Ticker: INCY
Reporting person: Sheila A. Denton
Relationship: Officer
Officer title: EVP & General Counsel
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Nov 17, 2025
Transaction code: S
Shares / units: 278
Price per share: $104.36
Acquired / disposed: Disposed (D)
Shares owned after: 26,569
Ownership form: Direct
Amendment: No

Footnotes from the filing

This includes an aggregate of 25,913 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance units that have not vested.